Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing proprietary technology platforms for cancer treatment. Its primary research centers on targeting neutrophil extracellular traps (NETs), which are implicated in cancer progression and treatment resistance. The company’s DNase I oncology platform aims to enhance cancer therapies across various indications, including pancreatic cancer and other solid tumors.
